Changing the future of Oncology.

About Sutro Biopharma

Sutro Biopharma is a clinical stage company pioneering a compelling and unique way of discovering, developing and manufacturing therapeutics. Our focus is aimed primarily on next generation cancer and autoimmune therapeutics — antibody conjugates, bispecific antibodies and cytokine derivatives. Unconstrained by traditional methods of cell-based discovery, we can design and develop targeted medicines by innovating outside the constraints of the cell.

Platform

Precision protein engineering generates superior molecules

Products

4 product candidates in the clinic as a result of Sutro’s research innovations

Partners

Premier collaborations with Bristol Myers Squibb, Merck, EMD Serono and
Vaxcyte (FKA – SutroVax)

People

Great people making excellence happen on behalf of patients, every day! 

We are honored to be named, BioSpace Best Places to Work for 2022. Many thanks to our Sutro team for their continuous efforts in placing our patients first. We appreciate and value all the work you have done! 
Click here to see the full list. 

Sutro Biopharma is honored to be included in Inc’s list of “Best-Led Companies”
Click here to see the full list. 

Technology

Using precise protein engineering and rational design, Sutro is advancing next-generation oncology therapeutics.

Our technology enables us to iteratively discover and test molecules in a rapid cycle of weeks rather than months, to rapidly identify optimal molecules designed for safety and potency.

Sutro’s proprietary and integrated cell-free protein synthesis platform XpressCF® and site-specific conjugation platform XpressCF+™ led to the discovery of STRO-001 and STRO-002, Sutro’s first two internally-developed ADCs. STRO-001 is a CD74-targeting ADC currently under investigation in a Phase 1 clinical trial for patients with advanced B-cell malignancies, and was granted Orphan Drug Designation by the FDA for multiple myeloma. STRO-002, a folate receptor alpha (FolRα)-targeting ADC, is currently being investigated in a Phase 1 clinical trial for patients with ovarian and endometrial cancers and was granted Fast Track designation by the FDA for ovarian cancer. A third product candidate, CC-99712, a BCMA-targeting ADC, which is part of Sutro’s collaboration with Bristol Myers Squibb, formerly Celgene Corporation, is enrolling patients for its Phase 1 clinical trial of patients with multiple myeloma and has received Orphan Drug Designation from the FDA. A fourth product candidate, M1231, a MUC1-EGFR, first-in-class bispecific ADC, which is part of Sutro’s collaboration with Merck KGaA, Darmstadt, Germany, known as EMD Serono in the U.S. and Canada (EMD Serono), is enrolling patients for its Phase 1 clinical trial of patients with metastatic solid tumors, non-small cell lung cancer (NSCLC) and esophageal squamous cell carcinoma. These four product candidates above being evaluated in clinical trials resulted from Sutro’s XpressCF® and XpressCF+™ technology platforms.

Pipeline

Sutro Biopharma is working independently and with partners to develop novel cancer therapies, including antibody-drug conjugates, bispecific antibodies and cytokine derivatives targeting immuno-oncology pathways.

Partnerships

Recent News

Careers and Culture

At Sutro, collaboration drives how we achieve results. By putting the goals of the Company first, we aim to make a difference in the lives of patients, both as individuals and as part of a team.